Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.40 |
| ▸ | TUBB | P07437 | 3/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28261345 | 0.71 | ALDH1A1 (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL9316441 | 0.71 | KDM4E (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL24404703 | 0.69 | IDO1 (0.44) | ALDH1A1HSD17B10LMNATP53MAPT | |
| SCHEMBL28151299 | 0.68 | KDM1A (0.40) | KDM4EALDH1A1HTR2CLMNATP53 | |
| SCHEMBL28151296 | 0.68 | KDM1A (0.40) | KDM4EALDH1A1HTR2CLMNATP53 | |
| SCHEMBL29690123 | 0.68 | MEN1 (0.38) | — | |
| SCHEMBL3000297 | 0.68 | MEN1 (0.38) | — | |
| SCHEMBL14767789 | 0.67 | TUBB4A (0.43) | POLBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29479374 | 0.66 | RET (0.35) | KDM4EHSD17B10HTR2CLMNATP53 | |
| SCHEMBL10609155 | 0.66 | RET (0.35) | KDM4EHSD17B10HTR2CLMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263763-B1 | TUBULIN BINDING LIGANDS | UNIV BAYLOR (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060142252-A1 | Tubulin binding agents and corresponding prodrug constructs | PINNEY KEVIN G | 2006-06-29 | — | — | US | disclosed |
| US-7001926-B2 | Tubulin binding agents and corresponding prodrug constructs | OXIGENE, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| WO-2004087061-A2 | TUBULIN BINDING AGENTS AND CORRESPONDING PRODRUG CONSTRUCTS | OXIGENE, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040043969-A1 | Tubulin binding agents and corresponding prodrug constructs | MATEON THERAPEUTICS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-6593374-B2 | Such as 3-(3'4'5'-trimethoxybenzoyl)-2-(3'benzylphosphate 4'methoxyphenyl)-6-methoxybenzo(b)thiophene; functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates useful as antitumor agents | BAYLOR UNIVERSITY | 2003-07-15 | — | — | US | disclosed |
| EP-1263763-A2 | TUBULIN BINDING LIGANDS AND CORRESPONDING PRODRUG CONSTRUCTS | BAYLOR UNIVERSITY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020055643-A1 | Tubulin binding ligands and corresponding prodrug constructs | MATEON THERAPEUTICS, INC. | 2002-05-09 | — | — | US | disclosed |
| WO-2001068654-A2 | TUBULIN BINDING LIGANDS AND CORRESPONDING PRODRUG CONSTRUCTS | BAYLOR UNIVERSITY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043969-A1 | Tubulin binding agents and corresponding prodrug constructs | TUBB4A, TUBB3, TUBB | POLB 568/4885TUBB4A 1/4885TUBB 3/4885 |
| US-20020055643-A1 | Tubulin binding ligands and corresponding prodrug constructs | TUBB, TUBB3, TUBB4A | POLB 578/4885TUBB4A 3/4885TUBB 1/4885 |
| US-20060142252-A1 | Tubulin binding agents and corresponding prodrug constructs | TUBB4A, TUBB3, TUBB | POLB 568/4885TUBB4A 1/4885TUBB 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.